

CO-EVOLUTION IN HIV ENZYMES

P. Boba, P. Weil, F. Hoffgaard and K. Hamacher

Bioinformatics & Theoretical Biology Group, Technische Universität Darmstadt, Germany

Keywords: Sequence analysis, Human immunodeficiency virus, HIV, Co-evolution, Mutual information, Data mining, Machine learning.

Abstract: Proteins as molecular phenotypes need to maintain their stability, fold, and the functionality throughout their individual and collective evolution. Such important properties are maintained by a selective pressure that reveals itself in sequence data sets. Small adaptive changes are usually possible, but in general the conservation of structure and function implies the co-evolution of amino acids within the molecule. We analyze two most important enzymes in the progression of viral infection by the human immunodeficiency virus (HIV) – namely the reverse transcriptase and the protease – under an information theoretical framework to derive insight into the selective pressure acting locally and globally on the enzymes. To this end we computed mutual information inside the proteins and between the proteins for some 40,000 sequences. We discuss the results of intra- and inter-protein co-evolution of residues in these enzymes and finally annotate important structural-evolutionary correlations. In particular we focus on the reverse transcriptase and a small signal indicating a potential co-evolution between the protease and the reverse transcriptase. We convinced ourselves that our sampling is sufficiently large and that no normalization schemes needs to be applied. We conclude with a short outlook into potential implications for drug resistance development.

1 INTRODUCTION

The acquired immunodeficiency syndrome (AIDS) is induced by the human immunodeficiency virus (HIV). Its viral replication cycle depends on the virus own protease and several other enzymes such as the reverse transcriptase. Currently the anti-HIV drugs target these two enzymes to prevent the maturation of new virions (Tsygankov, 2009; Wlodawer and Erickson, 1993).

Neutral evolution and drug resistance development have been under investigation for a long time: 1) the high mutation rate of HIV makes the virus an interesting evolutionary object in itself as it performs a large-scale mutagenesis study (Perelson et al., 1996); 2) a deeper knowledge of potential evolutionary barriers might lead to new therapeutics besides the HAART-procedure (Richman et al., 2009).

The theoretical understanding of the viral evolution has greatly improved over the recent years (Rong et al., 2007; Chen and Lee, 2006; Trylska et al., 2007; Hamacher and McCammon, 2006), even the biophysical annotation based on *in silico* models of the molecular dynamics is under way (Hamacher, 2008).

At the same time the wealth of information on HIV - in particular the large data sets of sequences

- prompt for a deeper analysis on the sequence level alone. Here we leverage an available data set of 45,161 mutant sequences of the HIV-1 protease (PR) and reverse transcriptase (RT).

2 MATERIALS AND METHODS

2.1 Sequence Data

The 45,161 positive selection mutant sequences have been collected by the Lee lab (Pan et al., 2007; Chen et al., 2004) and were made available on the net. The data set contains the genomic, nucleotide sequences from treated and untreated patients under various drug regimes. The individual entries are, however, not annotated by the drug treatment regime of the particular patient. We therefore find in this data set the diverse evolutionary dynamics, including effects such as neutral drift, drug resistance development, and other selective pressures on the two enzymes. Wherever a codon could not be mapped unequivocally to an amino acid we used a wild-card character, treating these cases similar to gaps.

For a comparison on the quality and potential

finite-size effects we created also sequence alignments with CLUSTALW (Thompson et al., 1994; Higgins and Sharp, 1988) and standard parameters on 1. BLAST (Altschul et al., 1990) hits on a sequence of viral ion channel Kcv, and 2. ribosomal proteins from bacterial genomes extracted by Pfam Hidden-Markov-Models (Finn et al., 2008).

2.2 Information Theoretical Measures on (Co-)Evolution

The evolution of an amino acid at a position i means a change in the symbols S^i over time within a set of acceptable values \mathcal{S} . One way to quantify the information content of such collections of symbols is the Shannon entropy (Shannon, 1951)

$$H^i := - \sum_{S^i \in \mathcal{S}} p(S^i) \cdot \log_2(p(S^i)) \quad (1)$$

where $p(S^i)$ is the probability of the occurrence of the symbol S^i within the empirical or theoretical data set under investigation. For empirical data sets one usually sets this probability to the frequency of the symbol within the data set. Positions (in e.g. a sequence alignment) with high entropy are then amino acids with high variability during evolutionary times. Our choice of \mathcal{S} comprised the 20 standard amino acids and the above mentioned wild-card character.

The *correlated* change in the amino acid composition within a molecule or between molecules is now based on empirical found two-point probabilities $p(S^i, S^j)$ for the co-evolution of positions i and j . We can define the Mutual Information (MI) between these positions as a relative entropy as follows (Lund et al., 2005):

$$\begin{aligned} \text{MI}^{i,j} &:= \sum_{S^i, S^j \in \mathcal{S}} p(S^i, S^j) \cdot \log_2 \left(\frac{p(S^i, S^j)}{p(S^i) \cdot p(S^j)} \right) \\ &= H^{i,j} - H^i - H^j \end{aligned} \quad (2)$$

The value of the MI gives the amount of information that one position i conveys about the other position j . The MI can be derived from the Kullback-Leibler divergence as a relative entropy, which has - besides sequence based approaches - also attracted attention as a measure in *in silico* drug design and molecular biophysics (Hamacher, 2007).

In addition we applied two normalization procedures to the MI in the following form, of which one was suggested earlier (Gloor et al., 2005) to account for potential sampling artefacts:

$$\begin{aligned} \text{MI}_{(2)}^{i,j} &:= \text{MI}^{i,j} / H^{i,j} \\ \text{MI}_{(1,1)}^{i,j} &:= \text{MI}^{i,j} / (H^i \cdot H^j) \end{aligned} \quad (3)$$




Figure 1: The median of the Mutual Information according to equation 2 for sequence homologs of the ion channel Kcv of plant viruses, bacterial ribosomal proteins S20 and S6, and the HIV-1 protease. We display the mutual information as a function of the number of sequences N included in the computation.

These normalizations are principally necessary to cope with finite data sets and potential absolute conservation of individual positions.

3 RESULTS

3.1 Finite Size Effects

To estimate size effects due to finite data we applied an established protocol: in figure 1 we show the MI as computed from randomized alignments of the listed molecules. The randomization was performed independently in each column by shuffling the characters. A perfect randomized sample would provide for an independence between columns i and j , and thus to a vanishing two-point-distribution function $p(S^i, S^j)$. This leads in equation 2 also to a vanishing $\text{MI}^{i,j}=0$. This allows to achieve an understanding of the statistical significance of a data set.

Clearly the data set for the viral enzymes under consideration is sufficient in comparison to the sequence collections for Kcv and ribosomal proteins. We analyzed this further and found the reason for this in the high gap content [data not shown] of the non-viral proteins chosen for comparison. The sequences for HIV-1 PR, on the other hand, do not contain any gap character at all, while the gap/wild-card character content for the RT is also negligible.

3.2 Effect of Normalization

We applied the two variants of the normalization procedure to the sequences of HIV-1 PR and RT. In figure 2 we show the change of the computed correlation measures under those normalization procedures. We applied a non-linear correlation measure - namely the Spearman ranking coefficient - that is superior in regard to the insight one gains into the relations between the two data sets.

We note in passing that the results for the two normalized MI variants $MI_{(2)}$ and $MI_{(1,1)}$ showed similar distributions.

We draw three conclusions from the observations in sections 3.1 and 3.2:

- effects to the finite-size of our data set are negligible
- $MI_{(2)}$ was shown (Gloor et al., 2005) to take finite-size effects most reliable into account
- the high Spearman correlation between $MI_{(2)}$ and MI indicate an equivalence

We therefore will in the subsequent parts of the discussion in this manuscript focus solely on the MI as there is no additional gain in using any normalization in this particular case.

3.3 Comparing Intra- and Inter-Protein Co-Evolution of Residues

In figure 3 we show distributions of the naked MI-values from our study on both, the HIV-1 PR and the HIV-1 RT, as well as the inter-MI for a potential co-evolution of residues in these enzymes.

We observe similarity of MI results for the *intra*-co-evolution within the individual, isolated enzymes. Obviously the evolutionary dynamics gave rise to the same overall “mutual information picture”.

The dissimilarity of the MI-distributions for the RT/PR and the one for the inter-molecular MI comes as no surprise: *within* a molecule the evolutionary pressure on the co-evolving dynamics of amino acids can be regarded as quite different in the evolutionary dynamics between residues in *different* molecules, despite potential protein-protein-interactions or other implicit interdependencies resulting from cell biological effects or drug combinations.

Although the RT consists of four domains – namely the finger, palm, thumb, connection domains – the potential for co-evolution between sites distributed over the four domains runs approximately in parallel to the scenario of the protease, both of which - in turn - are constructed as a molecular phenotype in form of homodimers.




Figure 2: Scatter plots of the natural logarithm of the MI values, comparing normalization procedures of eqs. 3.

a) $MI^{i,j}$ and $MI_{(2)}^{i,j}$; b) $MI^{i,j}$ and $MI_{(1,1)}^{i,j}$; c) $MI_{(1,1)}^{i,j}$ and $MI_{(2)}^{i,j}$. In each figure we give the Pearson correlation r_p and the Spearman ranking coefficient r_s (W.H. Press et al, 1995) between the data points. Note that MI values smaller than 10^{-8} were omitted for numerical reasons.

In figure 4 we show a graph for the MI of the HIV-1 PR that indicates structural as well as dynamical features as discussed in (Hamacher, 2008). We omit a picture for the RT as the molecule is too large to display single MI entries on single-pixel basis. The raw data, however, is available from our web-site (Boba and Hamacher, 2009) for future analysis¹.

¹Work is underway to construct a software-package to visualize such voluminous matrices as for the RT (Schreck




Figure 3: Comparison of the MI-values for the intra-protein co-evolution within the HIV-1 Protease (black) and the HIV-1 Reverse Transcriptase (blue). We compare to the *inter*-MI for the co-evolution between residues of the HIV-1 Protease on the one hand and the HIV-1 Reverse Transcriptase on the other (red).




Figure 4: The logarithm of the MI within the HIV-1 PR for all pairings of residue numbers. Clearly we reproduce features already found in (Hamacher, 2008) and have therefore verified our analysis protocol.

To analyze our MI results further and to overlay these with structural knowledge, we went on with a spectral decomposition of the MI matrices for the HIV-1 PR and HIV-1 RT. For the *inter*-MI values, that would indicate potential co-evolution between residues of different molecules, the MI matrix is, however, non-quadratic as the protein lengths are in general different. We therefore applied a singular et al., 2009).




Figure 5: The leading eigenvalues λ_k of a spectral decomposition of the MI-matrices. In black we show the ones for the (99×99) MI-matrix of HIV-1 PR, in blue for the (348×348) MI-matrix of HIV-1 RT (we restricted our analysis to the first 348 residues to cope with bad sequence resolution towards the C-terminus of the RT in the underlying data set). The red points give the singular values of the singular value decomposition (W.H. Press et al, 1995) of the *inter*-co-evolution matrix, which reflects MI-values between residues in the PR on the one hand and the RT on the other. The fast decay of the λ_k justifies a reconstruction of the respective MI-matrices by just a few, even only one eigenvector.

value decomposition (W.H. Press et al, 1995) to obtain a pseudo-spectral decomposition with respect to the singular values of the *inter*-MI matrix. The fast decay of the eigenvalues/singular values as shown in figure 5 indicates that a reconstruction of the whole MI matrices can be achieved by just a few eigenvectors, thus this small set of eigenvectors contains most, if not all, of the mutual information.

If we now overlay these eigenvectors onto the structures of the molecules, we can immediately connect structural and evolutionary information. This is done in figures 6 and 7.

Figures 6 and 7 both show high mutual information for secondary structure elements. In particular the β -sheet in the PR needs to be maintained as a structural basis of the fold of this protein. This is achieved by co-evolution of the residues within this element. In the RT the β -sheet close to the reactive center, as well as the α -helices forming the “finger” of the RT are structurally maintained by co-evolving the residues without giving them the freedom to independently mutate.

In figure 7 we show in addition relevant residues as small spheres. The colors indicate: yellow=three catalytic aspartic acids; green=residues that enhance




Figure 6: a) sequence entropy of the HIV-1 PR as in eq. 1; b) absolute values of the entries of the 1st eigenvector for the MI matrix of HIV-1 PR; c) absolute values of the entries of the 2nd eigenvector. We rescaled all values so that blue=maximum value, red=minimum value.

the excision reaction; red=non-nucleoside inhibitor binding pocket; black=residues involved in NRTI-resistance. This mapping was done in accordance with previous work (Sarafianos et al., 2004).

We note in passing that the level of conservation needs to be taken into account: an absolutely conserved position shows a MI of zero, always, as the knowledge about the identity of a residue here does not convey any information on any other position. We therefore decided to also display the sequence entropy of equation 1 as a measure of local sequence conservation in the figures 6 and 7. We return to this issue




Figure 7: I) a) sequence entropy of the HIV-1 RT as in eq. 1; b) absolute values of the entries of the 1st eigenvector for the MI of HIV-1 RT. II) viewed from orthogonal projection & rescaled as in fig. 6. The black part is the C-terminus for which we had only insufficient statistics; we omitted it from our analysis. The small spheres indicate functional sites as discussed in the text. Domains are indicated as follows: light blue="fingers", green="thumb", gray="palm".

in the discussion section.

Furthermore one can see the “correlation” of low sequence entropy and therefore the necessarily low mutual information in figure 8. In this figure we motivate the classification of an amino acid by its two evolutionary/co-evolutionary measures, that is the sequence variability as expressed by the entropy of eq. 1 and the contribution to mutual information correlation expressed by the respective entry in the leading eigenvector.

Class I (low sequence entropy, high MI) must be empty. Classes II and IV are the important ones for evolution: amino acids found in class IV are subject to extensive selective pressure to maintain their identity (low sequence entropy, thus small sequence variability). Evolution acts here *locally* to force *sequence stabilization*. Amino Acids in class II on the other hand can vary extensively (large sequence entropy), but at the same time convey information about other amino acids, thus show correlation with other sites within the protein. Accordingly the high MI reflects a selective pressure to maintain not a particular amino acid character, but instead to maintain some “interaction”. This “interaction” might be a physical, direct interaction such as steric repulsion or charge interactions, but could also reflect, e.g. folding properties of a monomer or recognition capabilities in protein-protein-binding mechanisms. One might hypothesize about the origin of this correlation or “interaction”, but a high MI indicates always a selective pressure to connect residues.

Class III on the other hand consists of those amino acids, which are highly variable (high sequence entropy), but at the same time show low dependence on other sites within the protein, and thus low connection via MI to these other positions.

3.4 Co-Evolution between Residues in the PR and the RT?

In figure 3 we have seen that the *inter*-MI is some two orders of magnitude smaller than the overall MI of the *intra*-MI. Combining this insight with the typical values found in MI studies as shown in figure 1 we nevertheless find a basal co-evolution between the two enzymes under investigation.

Although such a co-evolution is counter-intuitive at first sight, their might be some small or even unknown interdependencies between the two molecules. For example one effect might be due to the packing of RNA in the viral capsid and the genes coding for the enzymes are in close vicinity of the RNA. Such packing is highly susceptible to local charges and balances thereof - probably leading to long-range correlations




Figure 8: a) The correlation of MI contributions as found in the first eigenvector of the MI-matrix of PR vs. the respective sequence entropy of the amino acids in the PR. We applied an intuition driven classification scheme to decompose the results into four classes, numbered by Roman letters and illustrated by the red and green line. b) same as a), but for the RT.

along the genomic sequence. Additional potential effects are discussed in the discussion section 4.

In figure 9 we show our results for the pseudo-spectral reconstruction of the *inter*-MI between the PR and the RT.

4 DISCUSSION & SUMMARY

In this paper we have analyzed two of the most important enzymes for the progression of viral infection by the human immunodeficiency virus (HIV-1 protease and the HIV-1 reverse transcriptase) in an information theoretical setting to investigate evolutionary dynamics and extract positions under exceptional selective pressure.

A first insight is possible by looking solely at the sequence variability, which reveals selective pressure to maintain *local* properties within the molecule - local is meant here in the sense of an individual position. Sites of enzymatic action are prone examples of




Figure 9: Absolute values of the entries of the 1st left- and right-singular vector for a) the HIV-1 PR and b)+c) for the HIV-1 RT. Again we rescaled all values so that blue=maximum value, red=minimum value, and show the non-analyzed parts of the RT in black.

such findings.

Nevertheless molecular evolution provides for an extended selective pressure, which we label as *non-local* as it involves several amino acids at the same time. Despite individual amino acids being variable,

pairs of residues are connected or correlated. This is revealed by the mutual information they carry.

We have shown that our sampling statistics is sufficient and a standard normalization procedure usually applied is not necessary in our case - due to large sample size and absence of gaps in aligned sequences.

A particularly interesting result is the high sequences variability in the β -sheets of the PR, as shown in figure 6 a). At the same time we find these residues also to be relevant for the high MI (parts b & c of the same figure). This was recently discussed and annotated in a biophysical simulation setting (Hamacher, 2008).

At the same time, we find one residue (I54 in the wild-type) in the flaps to be highly variable and well correlated to other parts of the PR, see the blue residue in the upper strand of the β -sheet forming the flaps in figure 6.

Interestingly in figure 6 the dimerization interface of the PR in the lower part of the molecule shows over a larger range high sequence variability as well as large contributions to the mutual information. This indicates HIV-1's ability to vary the composition of the binding interface to dimerize the PR-monomers to become the PR-homodimer. Obviously maintaining recognition capabilities for binding is of paramount importance for the virus, revealing itself in the high MI.

The implications of relating sequence variability and mutual information can be seen in figure 8. An intuitive classification scheme can be justified on grounds of selective pressure induced by the ongoing evolution of these molecular phenotypes and divided in accordance with this classification procedure.

In table 1 we extracted the most pronounced residues under these classification schemes - the ones that correspond the most to the three existing classes. To this end we have chosen visually those residues most distant from the intersection of the red and green lines in figure 8.

We find in table 1 the L10 and M46 for the protease to be of class II. Correlated mutations in these positions are known to reduce binding of well-known protease inhibitors, such as JE-2147 by an order of magnitude or even more (Yoshimura et al., 1999; Reiling et al., 2002). This makes the acquisition of mutations relatively easy: these amino acids are not to be preserved, they only need to maintain "interactions" or correlations, thus opening the path to change the sequence locally in a correlated fashion to reduce drug efficiency while maintaining the structure, function, and thus the infectious outcome of the protease.

In class IV we found some of the amino acids building the flaps of the PR (res. no. 52-58 are usu-

HIV-1 PR				HIV-1 RT			
I	II	III	IV	I	II	III	IV
	63	41	49		334	102	349
	10	69	78		335	49	348
	71	57	29		329	108	347
	12	60	56		333	106	344
none	20	70	28	none	339	249	346
	7	61	27		338	48	343
	90	16	86		324	165	345
	82	39	52		322	100	342
	46	67	98		326	90	341
	54	92	51		311	4	152

Table 1: The most pronounced members of the classes as introduced in figure 8 for both enzymes. For class I no points exist that fulfill the particular requirement. The enumeration is in accordance with p66 monomer of the RT dimer. We used the numbering convention of (Prajapati et al., 2009; Sarafianos et al., 2004) for RT.

ally labeled to be part of the flaps). As is known from extensive simulations (Perryman et al., 2006) the flaps need to be most flexible to embrace the substrate of the PR. This - as indicated by our findings - is achieved evolutionary to strictly conserve the overall sequence composition of the flaps.

For the RT we find in table 1 the class III very interesting: residues of the binding pocket for the non-nucleoside inhibitors are to be found here. Class III contains, however, those positions that vary a lot, but do not show high correlation to other positions in the molecule. This implies that the amino acids binding the inhibitor can more or less freely mutate, because they are not correlated to other positions and thus there is not need for correlated mutations, which turned out to be necessary for the resistance development of the protease (see above).

We found some indications for a potential co-evolution between the PR and the RT. We can think of three reasons to this end:

The weak co-evolution between the proteins might be - as speculated in the results section - induced by implicit interactions of the coding genes during packing of the viral RNA into the capsid. Obviously charge distributions play a prominent role during these events and that might correlate (slightly) nucleotides and therefore also the coded amino acids. It is, however, reasonable to assume this effect to be distributed all over the proteins and not localized on particular residues.

Another selective pressure on both proteins is collectively induced by application of protease and reverse transcriptase inhibitors at the same time or in temporal proximity, as in e.g. HAART treatment (Richman et al., 2009), combining both types of in-

hibitors, for example lopinavir, ritonavir, tenofovir and emtricitabine. We note that we at least in the RT structure no contribution from portions of the complex that bind RT inhibitors can be observed, making this explanation less likely.

And finally one cannot completely neglect the possibility of functional protein-protein-interactions between the RT and the PR. Although there are currently no indications to this effect and we doubt that they exist, we mention this possibility for the sake of completeness here.

ACKNOWLEDGEMENTS

KH gratefully acknowledges financial support by the Fonds der Chemischen Industrie through the program Sachkostenzuschuß für den Hochschullehrernachwuchs.

Molecular Structures were visualized by VMD (Stone, 1998; Humphrey et al., 1996). VMD was developed by the Theoretical and Computational Biophysics Group in the Beckman Institute for Advanced Science and Technology at the University of Illinois at Urbana-Champaign.

REFERENCES

- Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. *J Mol Biol*, (3):403–410.
- Boba, P. and Hamacher, K. (2009). <http://bioserver.bio.tu-darmstadt.de/HIV>.
- Chen, L. and Lee, C. (2006). Distinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples. *Biology Direct*, 1(1):14.
- Chen, L., Perlina, A., and Lee, C. J. (2004). Positive Selection Detection in 40,000 Human Immunodeficiency Virus (HIV) Type 1 Sequences Automatically Identifies Drug Resistance and Positive Fitness Mutations in HIV Protease and Reverse Transcriptase. *J. Virol.*, 78(7):3722–3732.
- Finn, R. D., Tate, J., Mistry, J., Coghill, P. C., Sammut, S. J., Hotz, H.-R., Ceric, G., Forslund, K., Eddy, S. R., Sonnhammer, E. L. L., and Bateman, A. (2008). The Pfam protein families database. *Nucl. Acids Res.*, 36:D281–D288.
- Gloor, G., Martin, L., Wahl, L., and Dunn, S. (2005). Mutual information in protein multiple sequence alignments reveals two classes of coevolving positions. *Biochemistry*, 44(19):7156–7165.
- Hamacher, K. (2007). Information theoretical measures to analyze trajectories in rational molecular design. *J. Comp. Chem.*, 28(16):2576–2580.

- Hamacher, K. (2008). Relating sequence evolution of HIV-1 protease to its underlying molecular mechanics. *Gene*, 422:30–36.
- Hamacher, K. and McCammon, J. A. (2006). Computing the amino acid specificity of fluctuations in biomolecular systems. *J. Chem. Theory Comput.*, 2(3):873–878.
- Higgins, D. G. and Sharp, P. M. (1988). Clustal: a package for performing multiple sequence alignment on a microcomputer. *Gene*, 73(1):237–244.
- Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD – Visual Molecular Dynamics. *Journal of Molecular Graphics*, 14:33–38.
- Lund, O., Nielsen, M., Lundegaard, C., and Brunak, C. K. S. (2005). *Immunological Bioinformatics*. MIT Press, Cambridge.
- Pan, C., Kim, J., Chen, L., Wang, Q., and Lee, C. (2007). The hiv positive selection mutation database. *Nuc. Acids Res.*, 35:D371–D375(1).
- Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J., and Ho, D. (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science*, 271:1582–1586.
- Perryman, A. L., Lin, J.-H., and McCammon, J. A. (2006). Restrained molecular dynamics simulations of hiv-1 protease: The first step in validating a new target for drug design. *Biopolymers*, 82(3):272–284.
- Prajapati, D. G., Ramajayam, R., Yadav, M. R., and Giridhar, R. (2009). The search for potent, small molecule nrtis: A review. *Bioorganic & Medicinal Chemistry*, 17(16):5744–5762.
- Reiling, K., Endres, N., Dauber, D., Craik, C., and Stroud, R. (2002). Anisotropic dynamics of the JE-2147-HIV protease complex: Drug resistance and thermodynamic binding mode examined in a 1.09 Å structure. *Biochemistry*, 41:4582.
- Richman, D., Margolis, D., Delaney, M., Greene, W. C., Hazuda, D., and Pomerantz, R. J. (2009). The challenge of finding a cure for HIV infection. *Science*, 323:1304–1307.
- Rong, L., Gilchrist, M. A., Feng, Z., and Perelson, A. S. (2007). Modeling within-host HIV-1 dynamics and the evolution of drug resistance: Trade-offs between viral enzyme function and drug susceptibility. *J. Theo. Biol.*, 247:804–818.
- Sarafianos, S. G., Das, K., Hughes, S. H., and Arnold, E. (2004). Taking aim at a moving target: designing drugs to inhibit drug-resistant hiv-1 reverse transcriptases. *Current Opinion in Structural Biology*, 14(6):716–30.
- Schreck, T., Bremm, S., Held, S., and Hamacher, K. (2009). to be published.
- Shannon, C. E. (1951). Prediction and entropy of printed english. *The Bell System Technical Journal*, 30:50–64.
- Stone, J. (1998). *An Efficient Library for Parallel Ray Tracing and Animation*. Master's thesis, Computer Science Department, University of Missouri-Rolla.
- Thompson, J., Higgins, D., and Gibson, T. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.*, 22:4673–4680.
- Trylska, J., Tozzini, V., Chang, C., and McCammon, J. A. (2007). HIV-1 protease substrate binding and product release pathways explored with coarse-grained molecular dynamics. *Biophys. J.*, 92:4179–4187.
- Tsygankov, A. Y. (2009). Current developments in anti-HIV/AIDS gene therapy. *Curr Opin Investig Drugs*, 10(2):137–149.
- W.H. Press et al (1995). *Numerical Recipes in C*. Cambridge University Press, Cambridge.
- Wlodawer, A. and Erickson, J. (1993). Structure-based inhibitors of HIV-1 protease. *Annu. Rev. Biochem.*, 62(1):543–585.
- Yoshimura, K., Kato, R., Yusa, K., Kavlick, M. F., Maroun, V. and Nguyen, A., Mimoto, T., Ueno, T., Shintani, M., Falloon, J., Masur, H., Hayashi, H., Erickson, J., and Mitsuya, H. (1999). JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. *Proc. Natl. Acad. Sci.*, 96:8675–8680.